Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIa

 

 Permissions and Reprints

ABSTRACT

Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran). Specifically, the results of dose-finding studies for the prevention of venous thromboembolism after elective orthopedic surgery, the results of dose-finding studies for treatment of acute venous thromboembolism including prolonged prophylaxis of recurrent events, and the designs of ongoing clinical trials are reviewed.

REFERENCES

• 1 Hirsh J, O'Donnell M, Eikelboom J W. Beyond unfractionated heparin and warfarin: current and future advances.  Circulation. 2007;  116 552-560
  CrossrefPubMedGoogle Scholar
• 2 Bates S M, Weitz J I. The status of new anticoagulants.  Br J Haematol. 2006;  134 3-19
  CrossrefPubMedGoogle Scholar
• 3 Eikelboom J W, Weitz J I. A replacement for warfarin: the search continues.  Circulation. 2007;  116 131-133
  CrossrefPubMedGoogle Scholar
• 4 Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic.  Curr Top Med Chem. 2005;  5 1677-1695
  CrossrefPubMedGoogle Scholar
• 5 Bauer K A. New anticoagulants.  Hematology Am Soc Hematol Educ Program. 2006;  450-456
  PubMedGoogle Scholar
• 6 Turpie A GG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.  Arterioscler Thromb Vasc Biol. 2007;  27 1238-1247
  CrossrefPubMedGoogle Scholar
• 7 Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis.  IDrugs. 2004;  7 1028-1034
  PubMedGoogle Scholar
• 8 Herbert J M, Herault J P, Bernat A et al.. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting pentasaccharide.  Blood. 1998;  91 4197-4205
  PubMedGoogle Scholar
• 9 Bijsterveld N R, Vink R, Van Arken B E et al.. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.  Br J Haematol. 2004;  124 653-658
  CrossrefPubMedGoogle Scholar
• 10 The PERSIST Investigators . A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation.  J Thromb Haemost. 2004;  2 47-53
  CrossrefPubMedGoogle Scholar
• 11 The van Gogh Investigators . Idraparinux versus standard therapy for venous thromboembolic disease.  N Engl J Med. 2007;  357 1094-1104
  CrossrefPubMedGoogle Scholar
• 12 The van Gogh Investigators . Extended prophylaxis of venous thromboembolism with idraparinux.  N Engl J Med. 2007;  357 1105-1112
  CrossrefPubMedGoogle Scholar
• 13 Harenberg J, Joerg I, Hagedorn A, Giese C, Mikus G, Weiss C. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations after the vanGogh Trials.  Eur J Clin Pharmacol. 2008;  , in press
  PubMedGoogle Scholar
• 14 Savi P, Herault J P, Duchaussoy P et al.. Reversible biotinylated oligosaccharides, a new approch for a better management of the anticoagulant therapy.  J Thromb Haemost Suppl. 2007;  , abstract P-W-645
  PubMedGoogle Scholar
• 15 Harenberg J, Joerg I, Hagedorn A, Giese C. Bleeding and thromboembolic events after termination of therapy with idraparinux for prevention of recurrent venous thromboembolism-observation after the van Gogh Trials.  Blood. 2007;  110 , abstract 1877
  PubMedGoogle Scholar
• 16 Rezaie A R. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.  Thromb Haemost. 2003;  89 112-121
  PubMedGoogle Scholar
• 17 Dyke C K, Becker R C, Kleiman N S et al.. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.  Circulation. 2002;  105 2385-2391
  CrossrefPubMedGoogle Scholar
• 18 Alexander J H, Yang H, Becker R C on behalf of the XANADU-ACS Investigators et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XANADU-ACS trial.  J Thromb Haemost. 2005;  3 439-447
  CrossrefPubMedGoogle Scholar
• 19 Ansell J. Factor Xa or thrombin: is factor Xa a better target?.  J Thromb Haemost. 2007;  5(Suppl 1) 60-64
  CrossrefPubMedGoogle Scholar
• 20 Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.  Expert Opin Investig Drugs. 2006;  15 843-855
  CrossrefPubMedGoogle Scholar
• 21 Eriksson B I, Lars C, Borris L C for the ODIXa-HIP Study Investigators et al.. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.  Circulation. 2006;  114 2374-2381
  CrossrefPubMedGoogle Scholar
• 22 Agnelli G, Gallus A, Goldhaber S Z for the ODIXa-DVT Study Investigators et al.. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) The ODIXa-DVT Study.  Circulation. 2007;  116 180-187
  CrossrefPubMedGoogle Scholar
• 23 Buller H R. Once-daily treatment with an oral, direct factor Xa inhibitor- rivaroxaban (BAY 59-7939)-in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-finding study [abstract].  Eur Heart J. 2006;  27(Suppl) 761
  CrossrefPubMedGoogle Scholar
• 24 Pinto D J, Orwat M J, Koch S et al.. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.  J Med Chem. 2007;  50 5339-5356
  CrossrefPubMedGoogle Scholar
• 25 Lassen M R, Davidson B L, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.  J Thromb Haemost. 2007;  5 2368-2375
  CrossrefPubMedGoogle Scholar
• 26 Buller H R. A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis-The Botticelli Investigators.  J Thromb Haemost. 2007;  5(Suppl) , abstract O-S-003
  PubMedGoogle Scholar
• 27 Norman P. Medicinal Chemistry-12th RSC-SCI Symposium (Part I), Enzyme Inhibitors. Cambridge, UK; IDdb Meeting Report 2003
  Google Scholar
• 28 Agnelli G, Haas S K, Krueger K A, Ginsberg J S, Dmitrienko A, Brandt J T. A phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR.  J Thromb Haemost. 2007;  5 746-753
  CrossrefPubMedGoogle Scholar
• 29 Iwatsuki Y, Shigenaga T, Moritani Y et al.. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor.  Blood. 2006;  108 , abstract 911
  PubMedGoogle Scholar
• 30 Eriksson B I, Turpie A GG, Lassen M R for the Onyx Study Group et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.  J Thromb Haemost. 2007;  5 1660-1665
  CrossrefPubMedGoogle Scholar
• 31 Zafar M U, Vorchheimer D A, Gaztanaga J et al.. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.  Thromb Haemost. 2007;  98 883-888
  PubMedGoogle Scholar
• 32 Linkins L A, Weitz J I. Pharmacology and clinical potential of direct thrombin inhibitors.  Curr Pharm Des. 2005;  11 3877-3884
  CrossrefPubMedGoogle Scholar
• 33 Weitz J I. Factor Xa or thrombin: is thrombin a better target?.  J Thromb Haemost. 2007;  5(Suppl 1) 65-67
  CrossrefPubMedGoogle Scholar
• 34 Weitz J I, Buller H R. Direct thrombin inhibitors in acute coronary syndromes: present and future.  Circulation. 2002;  105 1004-1011
  CrossrefPubMedGoogle Scholar
• 35 Gustafsson D, Nystrom J, Carlsson S et al.. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res. 2001;  101 171-181
  CrossrefPubMedGoogle Scholar
• 36 Wolzt M, Sarich T S, Eriksson U G. Pharmacokinetics and pharmacodynamics of ximelagatran.  Semin Vasc Med. 2005;  5 245-253
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Harenberg J, Jörg I, Weiss C. Observations of alanine aminotransferase and aspratate aminotransferase in THRIVE studies treated orally with ximelagatran.  Int J Toxicol. 2006;  25 165-169
  CrossrefPubMedGoogle Scholar
• 38 Harenberg J, Jörg I, Weiss C. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.  Eur J Clin Pharmacol. 2006;  62 173-177
  PubMedGoogle Scholar
• 39 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long-term clinical trials of ximelagatran.  Drug Saf. 2005;  28 351-370
  CrossrefPubMedGoogle Scholar
• 40 Gurewich V. Ximelagatran-promises and concerns.  JAMA. 2005;  293 736-739
  CrossrefPubMedGoogle Scholar
• 41 Stangier K J, Rathgen K, Staehle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.  Br J Clin Pharmacol. 2007;  64 292-303
  CrossrefPubMedGoogle Scholar
• 42 Eriksson B I, Dahl O E, Buller H R et al.. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.  J Thromb Haemost. 2005;  3 103-111
  CrossrefPubMedGoogle Scholar
• 43 Ezekowitz M D, Reilly P A, Nehmiz G et al.. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).  Am J Cardiol. 2007;  100 1419-1426
  CrossrefPubMedGoogle Scholar

Job HarenbergM.D. 

Clinical Pharmacology Mannheim, Vascular Pharmacotherapy, Faculty of Medicine, University of Heidelberg

Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany

Email: job.harenberg@med.ma.uni-heidelberg.de